Last reviewed · How we verify
Safinamide Mesilate
Safinamide Mesilate, marketed by Eisai Korea Inc., holds a position in the pharmaceutical market with its key composition patent set to expire in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Safinamide Mesilate |
|---|---|
| Also known as | Equfina, ME2125 |
| Sponsor | Eisai Korea Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea (PHASE4)
- Effect of Safinamide on Parkinson's Disease Related Chronic Pain (PHASE4)
- Safinamide for Multiple System Atrophy (MSA) (PHASE2)
- Safinamide for Levodopa-induced Dyskinesia (PD-LID) (PHASE3)
- MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (PHASE3)
- Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Safinamide Mesilate CI brief — competitive landscape report
- Safinamide Mesilate updates RSS · CI watch RSS
- Eisai Korea Inc. portfolio CI